Donislecel

N/A

Report date: 2023/07/03 14:39:13

Base Information

Drug NameDonislecel
Drug Alias NameAllogeneic islets of Langerhans for transplant(Celltrans)LANTIDRA
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Pancreas-derivedCell and gene therapy > Cell therapy > Somatic cell > Pancreatic islet cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsDiabetes Mellitus, Type 1
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/06/28
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCelltrans Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrans Inc
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipedia